9.2 C
New York
Wednesday, February 8, 2023

Investing In DENTSPLY SIRONA Inc. (NASDAQ: XRAY): Why Should You?

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for DENTSPLY SIRONA Inc. (XRAY) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.33, or 0.92%, to $36.22. The DENTSPLY SIRONA Inc. has recorded 71,631 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Dentsply Sirona to Present at J.P. Morgan Healthcare Conference, Provides Update on Anticipated Full Year 2022 Results.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Stocks Info

The company is listed on the NASDAQ and operates within the Medical Instruments & Supplies industry segment. At the end of the last regular session, the stock closed at $35.89 and fluctuated between $37.19 as its day high and $35.64 as its day low. The current market capitalization of DENTSPLY SIRONA Inc. is $7.64B. A total of 2.04 million shares were traded on the day, compared to an average of 2.29M shares.

Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, XRAY has seen 26 BUY and 8 SELL insider trades, representing the acquisition of 1,039,584 and the disposition of 113,251 shares. Over the last 12 months, there were 81 BUYs and 37 SELLs from insiders. Insiders purchased 1,128,301 shares during that period but sold 145,405.

In the most recent transaction, LUCIER GREGORY T bought 6,000 shares of XRAY for 31.45 per share on Nov 15. After the transaction, the Director now owns 15,000 company shares. In a previous transaction on May 03, BRANDT ERIC sold 6,900 shares at 39.71 per share. XRAY shares that Director owns now total 35,155.


The dividend paying company demonstrates a positive outlook for investors and helps them generate immediate cash. XRAY’s most recent ex-dividend date was 12/29/2022 when it declared a $0.1250 quarterly dividend that was paid in cash on 1/13/2023. Previously, the company paid the dividend on 10/14/2022 with an ex-dividend date of 9/29/2022. The XRAY stock dividend was $0.1250 per share in cash.

It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for XRAY in the last 3 months, the mean price target is $34.91 with high estimates of $40.00 and low estimates of $29.00. In terms of 52-week highs and lows, XRAY has a high of $58.70 and a low of $26.48.

As of this writing, XRAY has an earnings estimate of $0.54 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of $0.6 per share and a lower estimate of $0.49. The company reported an EPS of $0.76 in the last quarter, which was -3.80% lower than expectations of $0.79.

Balance Sheet Annually/Quarterly

An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.

Analysts Opinion

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 13 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for XRAY is Hold with a score of 3.64. A total of 5 analysts rated the stock as Buy while 0 rated it as Overweight while 8 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles